Effects of inhaler therapy on mortality in patients with tuberculous destroyed lung and airflow limitation

References

• World Health Organization [homepage on the Internet]GenevaWorld Health Organization c2018 [updated September 18, 2018; cited October 10, 2018]2018 Available from: http://www.who.int/tb/publications/global_report/en/
   Google Scholar
• BobrowitzIDRodescuDMarcusHAbelesHThe destroyed tuberculous lungScand J Respir Dis197455182884854707
   PubMedGoogle Scholar
• SniderGLDoctorLDemasTAShawARObstructive airway disease in patients with treated pulmonary tuberculosisAm Rev Respir Dis197110356256405579906
   PubMed Web of Science ®Google Scholar
• LamKBJiangCQJordanREPrior TB, smoking, and airflow obstruction: a cross-sectional analysis of the Guangzhou Biobank Cohort studyChest2010137359360019820078
   PubMed Web of Science ®Google Scholar
• LeeJHChangJHLung function in patients with chronic airflow obstruction due to tuberculous destroyed lungRespir Med200397111237124214635980
   PubMed Web of Science ®Google Scholar
• KimSJLeeJParkYSEffect of airflow limitation on acute exacerbations in patients with destroyed lungs by tuberculosisJ Korean Med Sci201530673774226028926
   PubMed Web of Science ®Google Scholar
• RheeCKYooKHLeeJHClinical characteristics of patients with tuberculosis-destroyed lungInt J Tuberc Lung Dis2013171677523232006
   PubMed Web of Science ®Google Scholar
• YumH-KParkI-NEffect of inhaled tiotropium on Spirometric parameters in patients with tuberculous destroyed lungTuberc Respir Dis2014774167171
   PubMedGoogle Scholar
• KimCJYoonHKParkMJInhaled indacaterol for the treatment of COPD patients with destroyed lung by tuberculosis and moderate-to-severe airflow limitation: results from the randomized infinity studyInt J Chron Obstruct Pulmon Dis2017121589159628615931
   PubMed Web of Science ®Google Scholar
• MahlerDAWellsCKEvaluation of clinical methods for rating dyspneaChest19889335805863342669
   PubMed Web of Science ®Google Scholar
• CharlsonMEPompeiPAlesKLMackenzieCRA new method of classifying prognostic comorbidity in longitudinal studies: development and validationJ Chronic Dis19874053733833558716
   PubMedGoogle Scholar
• MillerMRHankinsonJBrusascoVStandardisation of spirometryEur Respir J200526231933816055882
   PubMed Web of Science ®Google Scholar
• TashkinDPCelliBSennSA 4-year trial of tiotropium in chronic obstructive pulmonary diseaseN Engl J Med2008359151543155418836213
   PubMed Web of Science ®Google Scholar
• CalverleyPMAndersonJACelliBSalmeterol and fluticasone propionate and survival in chronic obstructive pulmonary diseaseN Engl J Med2007356877578917314337
   PubMed Web of Science ®Google Scholar
• WedzichaJACalverleyPMSeemungalTAThe prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromideAm J Respir Crit Care Med20081771192617916806
   PubMed Web of Science ®Google Scholar
• WedzichaJABanerjiDChapmanKRIndacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPDN Engl J Med2016374232222223427181606
   PubMed Web of Science ®Google Scholar
• LeeCHKimKHyunMKJangEJLeeNRYimJJUse of inhaled corticosteroids and the risk of tuberculosisThorax201368121105111323749841
   PubMed Web of Science ®Google Scholar
• KimJHParkJSKimKHJeongHCKimEKLeeJHInhaled corticosteroid is associated with an increased risk of TB in patients with COPDChest201314341018102423079688
   PubMed Web of Science ®Google Scholar
• SuissaSPatenaudeVLapiFErnstPInhaled corticosteroids in COPD and the risk of serious pneumoniaThorax201368111029103624130228
   PubMed Web of Science ®Google Scholar
• EhrlichRIAdamsSBaatjiesRJeebhayMFChronic airflow obstruction and respiratory symptoms following tuberculosis: a review of South African studiesInt J Tuberc Lung Dis201115788689121477424
   PubMed Web of Science ®Google Scholar
• MenezesAMHallalPCPerez-PadillaRTuberculosis and airflow obstruction: evidence from the PLATINO study in Latin AmericaEur Respir J20073061180118517804445
   PubMed Web of Science ®Google Scholar
• WillcoxPAFergusonADChronic obstructive airways disease following treated pulmonary tuberculosisRespir Med19898331951982595036
   PubMed Web of Science ®Google Scholar
• PasipanodyaJGMillerTLVecinoMPulmonary impairment after tuberculosisChest200713161817182417400690
   PubMed Web of Science ®Google Scholar
• PlitMLAndersonRvan RensburgCEInfluence of antimicrobial chemotherapy on Spirometric parameters and pro-inflammatory indices in severe pulmonary tuberculosisEur Respir J19981223513569727784
   PubMed Web of Science ®Google Scholar
• Soler-CataluñaJJMartínez-GarcíaMARomán SánchezPSalcedoENavarroMOchandoRSevere acute exacerbations and mortality in patients with chronic obstructive pulmonary diseaseThorax2005601192593116055622
   PubMed Web of Science ®Google Scholar
• CelliBRCoteCGMarinJMThe body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary diseaseN Engl J Med Overseas Ed20043501010051012
   PubMed Web of Science ®Google Scholar
• DivoMCoteCde TorresJPComorbidities and risk of mortality in patients with chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2012186215516122561964
   PubMed Web of Science ®Google Scholar
• RyuYJLeeJHChunEMChangJHShimSSClinical outcomes and prognostic factors in patients with tuberculous destroyed lungInt J Tuberc Lung Dis2011152246i250i21219689
   PubMed Web of Science ®Google Scholar
• BriesacherBAAndradeSEFouayziHChanKAMedication adherence and use of generic drug therapiesAm J Manag Care200915745045619589012
   PubMed Web of Science ®Google Scholar
• HauptDKrigsmanKNilssonJLMedication persistence among patients with asthma/COPD drugsPharm World Sci200830550951418247154
   PubMed Web of Science ®Google Scholar
• IsmailaACorriveauDVaillancourtJImpact of adherence to treatment with tiotropium and fluticasone propionate/salmeterol in chronic obstructive pulmonary diseases patientsCurr Med Res Opin20143071427143624666181
   PubMed Web of Science ®Google Scholar
• KimJALimMKKimKParkJRheeCKAdherence to inhaled medications and its effect on healthcare utilization and costs among high-grade chronic obstructive pulmonary disease patientsClin Drug Investig2018384333340
   PubMed Web of Science ®Google Scholar
• RheeCKKimKYoonHKNatural course of early COPDInt J Chron Obstruct Pulmon Dis20171266366828255237
   PubMed Web of Science ®Google Scholar
• LimJUKimKKimSHComparative study on medical utilization and costs of chronic obstructive pulmonary disease with good lung functionInt J Chron Obstruct Pulmon Dis2017122711272128979113
   PubMed Web of Science ®Google Scholar